Given the well-established role of FOXC2 dysregulation in cancer, the results of Zhang et al. implicated the FOXC2 inducer FOXC2-AS1 as a novel oncogene, whose aberrant overexpression contributes to cancer development, progression and metastasis, and correlates positively with poor prognosis [208]. This evidence concerns the gene FOXC2 and cancer.